JUL 10, 2018 11:15 PM PDT

TdT Positive Cells - Not Just for Neoplasms

WRITTEN BY: Mauri Brueggeman

Terminal deoxyncleotidyl transferase (TdT) is a unique DNA polymerase molecule that is expressed by immature lymphoid cells, both normal and mutagenic.  As a cell ages, it loses the TdT expression capability.  Young lymph progenitor cells would be expected then to have this cell marker; cancerous lymph cells can be mutated versions of those young lymph progenitor cells growing out of control so increased TdT levels could be expected, and in fact have been used diagnostically in laboratory medicine.  TdT has been an identifiable marker since the late 1980s where it was found to be enhanced in acute undifferentiated leukemias, immature acute lymphoblastic leukemias, and in a fraction of cases of leukemic patients in blast crisis.  TdT acts by catalyzing the reaction that leads to the addition of deoxynucleotides to hydroxyl ends of oligonucleotides as part of DNA synthesis.  It also contributes to differences in antibody recognition sites by rearrangement of immunoglobulins or T-cell receptors.  It has long been associated with very undifferentiated neoplasms.

A new article published in the journal Human Pathology is a reminder that healthy lymph nodes and lymph cells can also express TdT because they are early lymphoid precursors; this is especially true in pediatric lymph nodes.  There are benign TdT positive lymph nodes in pediatric patients and this group focused on characterizing the presence of benign TdT positive cells and characterize the typical phenotype associated with their presence. 

Findings included that TdT was sparsely positive in all pediatric cases and in more than three quarters of adult lymph nodes evaluated (n=141).  It was noted that there was increased density of TdT positive cells in pediatric lymph nodes and TdT presence was not found to be associated with any clinical or histological factor other than identifying that these were lymphoid precursors with CD34 and CD10 also being expressed.

The study serves as a reminder to be mindful of the common phenotype of TdT positivity in early healthy lymphoid precursors and to carefully avoid misidentification of these cells as early neoplasm markers.

Sources: Human Pathology, International Journal of Biological Markers, American Journal of Clinical Pathology, Pathology Outlines,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
SEP 14, 2020
Cancer
We are too uneducated on the risks of colon cancer
SEP 14, 2020
We are too uneducated on the risks of colon cancer
A study conducted by researchers from Florida Atlantic University's Schmidt College of Medicine suggests that too ma ...
OCT 22, 2020
Cancer
Cancer cells don't like crowded spaces
OCT 22, 2020
Cancer cells don't like crowded spaces
Researchers collaborating from St. Anna Children's Cancer Research Institute Vienna, King's College London, Inst ...
OCT 28, 2020
Cancer
Protecting the Head and Neck from Off Target Radiation
OCT 28, 2020
Protecting the Head and Neck from Off Target Radiation
Radiotherapy alone or with chemotherapy is the go-to treatment for head and neck cancers. Unfortunately, head and neck t ...
OCT 30, 2020
Cancer
Fighting mesothelioma with curcumin
OCT 30, 2020
Fighting mesothelioma with curcumin
Research led by investigators at Flinders University in Australia is spearheading new developments in cancer prevention ...
NOV 14, 2020
Cancer
New intravenous anti-cancer therapy crosses blood-brain barrier
NOV 14, 2020
New intravenous anti-cancer therapy crosses blood-brain barrier
New research from the University of Michigan reports for the first time a new synthetic protein nanoparticle that is abl ...
NOV 26, 2020
Immunology
Armed With ImmunoBait, Red Blood Cells Fight Lung Cancers
NOV 26, 2020
Armed With ImmunoBait, Red Blood Cells Fight Lung Cancers
  There’s a new weapon in the battle against lung cancer metastases: red blood cells equipped with nanopartic ...
Loading Comments...